Thursday, November 19, 2026

Subscribe

NewsEdition DR CongoDR Congo

DR Congo: experimental Ebola vaccines must prove effective against Bundibugyo

Two vaccine candidates targeting the Bundibugyo virus have been included in a clinical trial in the Democratic Republic of the Congo. Initial results allow their evaluation to continue, but their effectiveness remains to be established.

African health officials meet around a table during a coordination meeting in Kinshasa.

A vaccine effective against one strain of Ebola does not automatically protect against all the others. In the Democratic Republic of the Congo (DRC), this distinction between viruses carries great weight: against Bundibugyo, health teams must still establish whether experimental vaccines can prevent the disease.

The stakes extend beyond laboratories. In affected areas, health workers must detect cases, trace contacts and address community concerns at the same time. In Kinshasa, health authorities and the National Institute of Biomedical Research (INRB) are central to the response and the clinical evaluation.

Two candidates under study, not yet authorised vaccines

On 4 November 2026, the World Health Organization (WHO) made public the recommendation of its technical group: to include two candidates specifically targeting the Bundibugyo virus in the phase 2/3 trial being conducted in the DRC. They are ChAdOx1 BDBV, developed by the University of Oxford and the Serum Institute of India, and mRNA-1469, developed by Moderna. The recommendation concerns their evaluation in a trial; it is neither marketing authorisation nor proof of efficacy.

The WHO report cites preliminary safety and immunogenicity data, meaning the ability of a candidate to trigger an immune response. These results allow the evaluation to continue, but do not show that the vaccines prevent infection or severe illness. The trial must still produce the evidence needed to assess their efficacy and monitor adverse effects.

Ervebo, the vaccine already authorised against the Zaire Ebola virus, should not be confused with established protection against Bundibugyo. The WHO notes that no vaccine is licensed against this strain. The addition of the two candidates to the trial therefore addresses a specific gap, rather than the failure of a vaccine designed for this virus.

Research in the DRC amid a regional emergency

The DRC has already faced several Ebola outbreaks. But each episode depends on the strain in circulation and the resources available locally. Bundibugyo was identified in previous epidemics, notably in Uganda in 2007-2008 and in the DRC in 2012. The current outbreak has reached an exceptional scale: figures published in early November report more than 5,000 deaths, according to data released by the Congolese authorities and reported by the Associated Press. The toll changes as investigations proceed and cases are confirmed.

The trial is led by the INRB, a Congolese biomedical research institution, with international partners and support from the WHO. This local responsibility matters: national teams help shape the research and produce data in the context where the epidemic is spreading. The availability of doses, the follow-up of participants and the ability of health centres to conduct the trial over time remain decisive.

The crisis also has a cross-border dimension. Africa CDC, the African Union’s public health agency, has incorporated the risk of regional spread into its preparedness plan. Border surveillance and the rapid sharing of information between neighbouring countries therefore matter as much as the trials conducted in the DRC. Regional coordination must, however, complement national arrangements, not replace the Congolese health authorities.

A vaccine cannot replace care or trust

While robust results are awaited, the response relies on several measures at once. Rapid diagnosis and early treatment can limit complications. Monitoring people who have been in contact with a case helps identify new infections. Appropriate isolation and safe burials reduce the risks of transmission, provided they are organised with families and communities.

These measures do not have the same effects everywhere. In cities, health facilities may be closer, but travel and population density can sometimes make follow-up more difficult. In remote areas, the distance to care and the availability of teams can delay diagnosis. For people who depend on trade or informal work, isolation can also mean an immediate loss of income. The health response must take these practical constraints into account if it is to be followed and effective.

Trust is also an operational factor. Experimental vaccination requires clear information about what is known, what remains uncertain and the conditions for participation. Presenting the candidates as already effective could muddy the message. Conversely, explaining that the trial is specifically intended to measure their benefit helps distinguish research from a routine vaccination campaign.

What the next results must establish

The priority now is to monitor the trial’s progress and the publication of its results: the number of participants, observed adverse events, immune response and any protection against the disease. The WHO has documented the recommendation process in its report on Bundibugyo vaccine candidates. The Congolese authorities and research teams will also need to report on how the trial is integrated with care and epidemiological surveillance.

For Central Africa, the challenge is twofold: to respond to the current epidemic and strengthen the capacity to develop, test and evaluate health tools on the continent. Cooperation between the WHO, the African Union and scientific partners can support this effort, but decisions and data produced in the DRC will remain essential. At this stage, the two candidates open up a research avenue; they do not yet provide proven protection.

Automatic translation. Original French version

News quiz

Edition DR CongoDR Congo: the news quiz for 14–15 November

5 questions